Introduction
============

Fibrotic disease is a kind of chronic hypoxia related disease with pathogenesis that includes increased extracellular matrix (ECM) deposition, and widespread vasculopathy ([@B28]). Fibrosis is increasingly seen as the result of deregulated tissue repair in response to chronic hypoxia that results in the excessive accumulation of ECM. Severe chronic hypoxia is overt in involved tissues of fibrotic disease patients ([@B17]). There are a variety of mechanisms leading to persistent chronic hypoxia. First, continuous and extensive microangiopathy caused by inflammation ([@B47]; [@B12]) or metabolic stress ([@B64]; [@B89]) is regarded as an early and possibly the earliest pathogenic event in the fibrotic disease ([@B48]) that leads to chronic hypoxia. Chronic hypoxia in turn induces vascular remodeling ultimately giving rise to progressive luminal narrowing and blockage ([@B26]) resulting in progressive exacerbation of the chronic hypoxic state. Moreover, excessive deposition of ECM, the hallmark of fibrosis ([@B7]), further worsens hypoxia by increasing diffusion distances between blood vessels and tissue cells and increased tissue pressure. Extensive microangiopathy, vascular remodeling, and ECM deposition leads to vascular rarefaction and chronic hypoxia that directly contributes to progressive amplification of fibrosis. Increasing evidence has demonstrated that chronic hypoxia is actively involved in the pathogenesis of fibrosis ([@B38]) by stimulating the production of ECM including fibronectin-1, IGF-binding protein 3 ([@B16]), collagens, and collagen-modifying enzymes such as COL4A1, COL4A2, COL5A1, COL9A1, COL18A1, procollagen prolyl hydroxylases (P4HA1 and P4HA2), and lysyl hydroxylases (procollagen lysyl hydroxylase and procollagen lysyl hydroxylase 2)([@B59]). Hence, persistent and extensive chronic hypoxia is a distinctive feature of fibrotic disease that definitely aggravates tissue fibrosis.

Hypoxia inducible factors (HIFs) are regarded as the "master regulators" ([@B43]) in response to the hypoxic environment and are essential for mediating adaptive reactions to hypoxia ([@B2]; [@B22]). HIFs are in a family of basic--helix-loop-helix/Per-ARNT-Sim (bHLH/PAS) DNA binding transcription factors ([@B31]) and are heterodimers composed of two different subunits: HIF-α, that is oxygen regulated, and HIF-β, that is expressed constitutively in the nucleus ([@B86]; [@B73]). There are at least three α subunits-HIF-1α, HIF-2α, and HIF-3α, that accumulate in the cytoplasm and translocate into the nucleus to form heterodimers with a β subunit. After translocating to the nucleus, the HIF heterodimers associate with co-activators and bind to hypoxia response elements (HREs) in gene promoters to initiate gene transcription ([@B46]; [@B74]). Hypoxia induces stabilization and nuclear translocation of HIF-α subunits and their transcriptional activity ([@B46]) by inhibiting the activity of both prolyl hydroxylases and factor-inhibiting HIF1. Hypoxia increases the half-life of HIF-1α from 5 min to approximately 60 min ([@B40]).

Compelling evidence indicates that HIF-1α plays a key role in vascular remodeling under hypoxic conditions ([@B98]). The extensive and cumulative vascular remodeling in arterioles that accompanies chronic hypoxia results in multiple internal organ fibrosis and pulmonary hypertension (PH). Of note, PH associated with pulmonary fibrosis is the major cause of mortality in individuals suffering from fibrotic disease, such as SSc, and accumulating evidence has revealed that HIF-1α is implicated in producing excessive ECM which was the underlying cause of fibrosis ([@B16]; [@B36]; [@B33]; [@B83]; [@B104]; [@B30]; [@B61]). Fibrosis is typically characterized by prolonged and/or exaggerated activation of fibroblasts ([@B38]). Strong and stable expression of HIF-1α was found in fibrotic dermal fibroblasts cultured under hypoxic conditions, 1% oxygen, equivalent to a PO~2~ value of 7 mmHg, which is close to the 10th percentile measured in involved dermal areas of fibrotic disease patients ([@B39]; [@B16]). Furthermore, increased expression of HIF-1α occurred in subcutaneous fibroblasts from healthy skin ([@B60]) and fibrotic skin ([@B34]) exposed to hypoxic conditions *in vitro*. Fibroblasts isolated from human arteries also exhibited a remarkable up-regulation of HIF-1α under hypoxic conditions ([@B54]). In a more detailed study, HIF-1α completely translocated from the cytosol into the nucleus ([@B92]) in dermal fibroblasts from fibrotic disease patients after hypoxic exposure ([@B17]). HIF-1α expression is elevated in a number of fibrotic diseases ([@B25]; [@B4]; [@B102], [@B103]) and overt up-regulation of HIF-1α in the skin of naïve SSc patients was observed compared with normal skin ([@B44]) further suggesting that HIF1α is involved in the pathogenesis of fibrotic disease, particularly in SSc ([@B94]). In addition, HIF-1α is particularly related to subgroups of SSc patients with prominent vascular manifestations ([@B94]). Inhibition of HIF-1α is therefore a rational strategy for novel therapeutic development since effective therapies are not yet available for fibrotic disease, such as SSc.

Hif-1α and ECM (**Figure [1A](#F1){ref-type="fig"}**)
=====================================================
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Fibrosis is characterized by excessive deposition of ECM in organs or tissues including different kinds of collagens, hyaluronic acid, fibronectin, and proteoglycans ([@B38]). HIF-1α contributed to the up-regulated gene expression for several ECM and non-ECM in fibroblast cultures *in vitro*.

Increased expression of pro α2 (I) collagen (COL1A2), thrombospondin (TSP) 1, and transforming growth factor β--induced protein (TGF βi) were observed in both mouse embryonic and human dermal fibroblasts under hypoxic conditions ([@B16]). [@B6] demonstrated that HIF-1α induced collagen hydroxylation and normal collagen secretion in the hypoxic milieu by directly activating transcription of the collagen prolyl 4-hydroxylase enzyme (P4H) and pyruvate dehydrogenase kinase 1 (Pdk1). HIF-1α deficiency resulted in impaired collagen secretion in the presence of hypoxia. Similarly, HIF-1α mediates ECM accumulation through NADPH oxidase (NOX) *in vitro* in cultured renal mesangial cells ([@B61]). Microarray genome expression profiling from skin biopsies of fibrotic disease patients revealed that a prominent alteration in gene expression underlying fibrosis is within the transforming growth factor β (TGF-β) pathway ([@B93]), and TGF-β was closely involved in the induction of ECM ([@B21]). However, HIF-1α is upstream of TGF-β production, and hypoxia-induced TGF-β production requires HIF-1α ([@B104]). [@B68] demonstrated that inhibition of HIF-1α reduced TGF-β expression *in vivo* as well.

Epithelial-to-mesenchymal transition (EMT) can be characterized by acquisition of mesenchymal markers such as α-smooth muscle actin (α-SMA). EMT results in the production of more ECM including α-SMA and vimentin ([@B78]; [@B100]) and requires HIF-1α expression ([@B104]). [@B36] demonstrated that increased HIF-1α expression may promote fibrogenesis by facilitating EMT. Plasminogen activator inhibitor-1 (PAI-1), found in the ECM ([@B66]) and a key inhibitor of fibrinolysis ([@B13]), inhibited proteolytic processes that were linked with fibrosis ([@B20]). HIF-1α heterodimers with HIF-1β induced by hypoxia *in vivo* bind HRE in the PAI-1 promoter and induce PAI-1 expression ([@B50]). Lysyl oxidase (LOX) is important for normal synthesis of collagen and elastin ([@B29]; [@B62]). LOX is a transcriptional target for HIF-1α-HIF-1β heterodimers ([@B33]) that translocate into the nuclear compartment of fibrogenic cells ([@B57]) and is up-regulated during fibrogenesis. [@B36], [@B33] showed that HIF-1α could up-regulate the expression of LOX *in vivo* and *in vitro*, leading to the accumulation of collagen and other components involved in establishing and remodeling the ECM. [@B33] pinpointed LOX as a key player in HIF-1α mediated deposition of ECM. Furthermore, connective tissue growth factor (CTGF) has been reported to enhance cell proliferation and ECM production in fibroblasts ([@B27]). Mounting evidence has demonstrated that expression of CTGF is upregulated during fibrotic disorders ([@B42]; [@B45]; [@B55]; [@B37]), and in hypoxia, the induction of CTGF is directly mediated by HIF-1α-HIF-1β heterodimer binding to the CTGF associated HRE ([@B35]). In summary, HIF-1α is ubiquitous in many different tissues ([@B86]) and in fibrotic disease contributes to persistent pathofibrogenesis in multiple organs by stimulating production of excessive ECM.

HIF-1α and Vascular Remodeling (**Figure [1B](#F1){ref-type="fig"}**)
=====================================================================

Vascular remodeling is primarily composed of dysregulated proliferation of endothelial cells (ECs) and an increase in the number (hyperplasia) and volume (hypertrophy) of arterial smooth muscle cells (ASMC) resulting in progressive vascular occlusion and chronic hypoxia. High expression of HIF-1α within endothelial plexiform lesions ([@B82]) and ASMC ([@B8]) suggests a strong correlation between HIF-1α and proliferative vasculopathy.

Arterial smooth muscle cells hyperproliferation in the media of the artery was suggested to be the key event in vascular remodeling ([@B11]). Transient receptor potential channel (TRPC) 1, a non-selective cation channel, is permeable to Ca^2+^ ions. Increase in levels of TRPC1 mediated by bone morphogenetic protein4 (BMP4) ([@B87]) was HIF-1α dependent in ASMC ([@B88]). Reduction in voltage-gated K^+^ currents, resulting in membrane depolarization and activation of voltage-dependent Ca^2+^ channels and subsequently increasing Ca^2+^ influx, was regulated by HIF-1α as well ([@B77]). Both voltage-gated K^+^ (Kv) channels and TRPC1, mediated by HIF-1α, contributed to an increase in cytosolic free Ca^2+^ which was a major trigger for ASMC proliferation ([@B84]). ASMC proliferation may be a consequence of up-regulated aquaporin 1 as a result of the increased cytosolic free Ca^2+^ ([@B99]). Furthermore, both TRPC1 silencing by small interfering RNA (siRNA) and TRPC1 knockout impaired hypoxia-induced ASMC proliferation *in vitro*, and TRPC1^-/-^ mice had less vascular muscularization compared with wild type mice ([@B58]). In addition, hypoxic induction of the Na^+^/H^+^ exchanger isoform 1 (NHE1) expression and alkalinization of intracellular pH were regulated by HIF-1α ([@B76]). Both activation of the Na^+^/H^+^ exchanger and alkalinization of intracellular pH were necessary for ASMC proliferation ([@B69]). [@B101] demonstrated that HIF-1α transcriptionally upregulated the expression of miR-322 in hypoxia, which led to proliferative responses of ASMC due to direct targeting of BMPR1a and smad5. Similarly, Platelet derived growth factor bb (PDGFbb) can induce proliferation of ASMC *in vitro* and *in vivo* ([@B70]). PDGFbb-induced signaling gave rise to the hypertrophy of ASMC both *in vitro* and *in vivo* ([@B49]) via excessive deposition of hyaluronic acid (HA) in smooth muscle cells ([@B67]). The possible mechanism is through tyrosine 31 (Y31) and 118 (Y118) phosphorylation of paxillin, which was attenuated by HIF-1α knockdown ([@B85]).

Similarly, HIF-1α is also involved in the proliferation of ECs. Abnormally proliferating ECs are characterized by low numbers of mitochondria ([@B97]). Knockdown of HIF-1α increased the numbers of mitochondria in ECs *in vitro* ([@B24]) and suggests that the reduced mitochondria number in abnormally proliferating ECs may be a consequence, at least in part, of increased HIF-1α expression. HIF -1α inducible factors include hepatocyte growth factor (HGF) ([@B53]) and stromal-derived factor-1a (SDF-1a) ([@B9]). A special kind of hematopoietic endothelial stem cell, CD34^+^CD133^+^hemangioblast, may promote angioproliferative vascular remodeling ([@B3]). Local production of chemoattractants, such as SDF-1α and HGF, by diseased endothelium can recruit substantial numbers of CD34^+^CD133^+^hemangioblasts to sites of angioproliferative vascular remodeling ([@B23]). Both signal transducers and activators of transcription (STAT) 3 ([@B96]) and chloride intracellular channel 4 (CLIC4) ([@B95]) contribute to the hyperproliferative pathology of ECs invoking another important role for HIF-1α in vascular fibrosis.

Targeting HIF-1α in Fibrosis
============================

Studies to date indicate that HIF-1α is intimately involved in persistent pathofibrogenesis, vascular remodeling, and PH in fibrotic disease. Severe, multiple organ fibrosis associated with the continuous accumulation of HIF-1α, caused by chronic or prolonged hypoxia in fibrotic disease, suggests that HIF-1α maybe a promising target for novel fibrotic disease treatments, such as SSc.

Recently, hypoxic prodrugs, projecting to be specifically activated in the low O~2~ milieu, deliver the active agent to hypoxic tissues through reduction of the prodrug by cellular reductases ([@B65]). These hypoxic prodrug agents may significantly alleviate off-target effects of the biological therapy by limiting active drug to hypoxic tissue and only inhibiting HIF-1α in hypoxic tissues. Gene therapy targeting HIF-1α may also be effective for therapy in hypoxia-related diseases as well ([@B80]; [@B90]; [@B15]; [@B10]). In addition, the therapeutic benefits of HIF-1α inhibitors would be maximized in the presence of delivery carriers that eliminate pharmacokinetic and stability problems and minimize potential systemic toxicity. For example, liposomes and nanoscale-based drug delivery systems may be applied as a delivery assistant for HIF-1α gene therapy ([@B90]; [@B10]). The most successful example of a successful liposomal drug delivery system may be that for Amphotericin B, which has been widely applied in the clinic for treating invasive fungal infections. Amphotericin B is a highly effective drug but with potential severe toxic side effects ([@B5]; [@B91]). Amphotericin B encapsulated in liposome has significantly reduced toxicity as well as increased therapeutic benefit when administered systemically encapsulated within liposomes ([@B81]; [@B1]). Antisense oligonucleotides targeted to HIF-1α mRNA combined with doxorubicin were successfully delivered to oncocytes by poly (ethylene glycol) polymer (PEGylated) liposomes as drug carriers ([@B90]). Furthermore, YC-1 \[3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole\], a HIF-1α inhibitor, reduced ECM accumulation *in vivo* ([@B61]). Trichostatin A, identified indirectly to down-regulate HIF-1α, has been applied in clinical trials in patients with cancers ([@B51]) and has been shown to reduce the release of collagen from fibrotic dermal fibroblasts *in vitro* ([@B41]). In conclusion, a viable therapy option for fibrotic disease may include agents that target and inhibit HIF-1α since delivery vehicles may help reduce off-target effects and enhance therapeutic efficiency ([@B75]).

On the other hand, HIF-1α has been repeatedly observed to assist wound healing through inflammation, angiogenesis, vasculargenesis, and fibroplasia in acute injury ([@B71], [@B72]). The most prominent contraindication for systemic administration of HIF-1α inhibitors, therefore, is trauma. An analogy for adverse effects that may accompany biological therapy to inhibit HIF-1α may be tumor necrosis factor-α (TNF-α) inhibitors in rheumatic diseases. TNF-α inhibitors inhibit inflammation that is necessary for tissue repair. HIF-1α is required for repair in acute injury as well ([@B14]). In particular, we need to be vigilant about physiological repair events such as menstruation within the context of HIF-1α inhibitor administration.

Persistent and remarkable up-regulation of vascular endothelial growth factor (VEGF) has been observed in all stages of fibrotic disease ([@B17]) and actively proliferating ECs of plexiform lesions ([@B82]). VEGF is the predominant proangiogenic factor regulated by HIF-1α in other hypoxia related diseases, but VEGF up-regulation and consequent massive and extensive microangiopathy in fibrotic disease is HIF-1α independent, even with hypoxia ([@B17]). HIF-1α expression did not correlate with up-regulated VEGF in affected tissues from patients suffering from fibrotic disease ([@B17]). Since HIF-1α is critical for VEGF up-regulation in other hypoxia related diseases, consideration must be given to the question of whether deceased VEGF after systemic HIF-1α inhibition may severely decrease and impair neoangiogenesis. The worry may be unnecessary for fibrotic disease and its associated massive and extensive microangiopathy in affected tissues and organs. Up-regulated expression of VEGF is also driven by interleukin-1β, PDGF, and TGF-β, all of which are up-regulated in fibrotic disease and can stimulate the expression of VEGF ([@B63]; [@B52]). Moreover, the role played by HIF-2α and HIF-3α in the over-expression of VEGF has not yet been extensively investigated. Above all, sufficient tissue vascularization depends on strict regulation of VEGF expression rather than on persistent up-regulated expression of VEGF ([@B17]). The formation of chaotic vessels, feathered with glomeruloid and haemangioma-like morphology, was partly due to chronic and uncontrolled over-expression of VEGF ([@B19]; [@B79]). [@B18] designed an animal model system in which a source of VEGF could be specifically induced and steadily maintained for a desired duration and then subsequently switched off. Time-dependent regulation of VEGF expression was necessary for adequate and normal vascularization ([@B18]). Persistent, uninterrupted exposure to VEGF led to formation of irregularly shaped, sac-like vessels resulting in decreased blood flow compared to normal, mature, functional blood vessel formation after short-term over-expression of VEGF ([@B18]). Irregularly shaped, sac-like vessels observed in nailfold, a prominent character of the prototypic fibrotic disease**-**SSc ([@B56]), may also suggest that persistent up-regulated expression of VEGF is involved in fibrotic disease, and is harmful rather than beneficial, regardless of whether VEGF is HIF-1α independent in fibrosis ([@B17]). Other angiogenic factors contribute less to neovascularization and have no effect on irregular and sac-like vessels in the presence of persistent and remarkable up-regulation of VEGF. The US FDA approved FTY720 inhibits HIF-1α accumulation by inhibiting the S1P signaling pathway. FTY720 transformed a chaotic vascular network to vascular normalization while simultaneously and subsequently redressing hypoxia *in vivo* and *in vitro* ([@B32]). That result gives further credence to the suggestion that HIF-1α is implicated in chaotic angiogenesis. This result also suggests that targeting HIF-1α would be a viable strategy for fibrotic disease, such as SSc, without impairing normal angiogenesis.

Conclusion
==========

HIF-1α *per se* is helpful in repairing injury and correcting hypoxia via multiple mechanisms, however, prolonged exposure to HIF-1α is harmful and contributes to persistent pathofibrogenesis in fibrotic disease (**Figure [2](#F2){ref-type="fig"}**). Furthermore, fibrosis in organs resulting in organ failure accounts for much of the morbidity and mortality associated with fibrotic disease. SSc is prototypic multisystem fibrotic disease and present immunosuppressive therapy exhibits intolerable side effects without selectively targeting the immunopathogenic mechanisms responsible for SSc. In addition, fibrosis in SSc is not restricted to a single organ, but rather involves multiple internal organs and skin. Biotherapy targeting HIF-1α, therefore, is a promising therapeutic alternative that is more likely to confer therapeutic benefits specific to fibrotic disease, particularly to SSc, by attenuating fibrosis and terminating or delaying vascular remodeling.
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